A Study to Evaluate the Efficacy and Safety of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells in Transfusion-dependent β Thalassemia Patients is a NA clinical asset sponsored by Institute of Hematology & Blood Diseases Hospital, China in Thalassemia, Beta, Thalassemia Major. SEO and diligence focus: VGB-Ex01, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.